The study is evaluating a pan-RAS mRNA vaccine (Seq ID No. 70, WO 2022/081764 A1) targeting KRAS mutations such as G12D, G13D, L19F, A59T, G60D, Q61H and K16, suitable for pancreatic ductal adenocarcinoma (PDAC), where KRAS codon 12 mutations account for more than 90% of cases. Immunoinformatic analyzes predicted epitopes for cytotoxic T lymphocytes (CTL), helper T lymphocytes (HTL) and B cells with favorable antigenicity, without allergenicity and toxicity. The construct is stable, hydrophilic, with a molecular weight of 21,973.98 Da, optimal expression (CAI = 0.956; GC = 61.7%) and stable interactions with TLR7/8 according to 500 ns docking and dynamics simulations. SASA analysis confirmed strong exposure of epitopes to solvents, promoting immunogenicity. Immune simulations predicted strong cellular and humoral responses. The vaccine demonstrates structural stability and immunogenic potential for PDAC, with possible synergy with resiquimod (R848), requiring experimental validation and toxicity for clinical use.